One__O of__O just__O two__O interferon-gamma__O release__O assays__O (IGRAs)__B-ORG recommended__O by__O the__O Centers__B-ORG for__I-ORG Disease__I-ORG Control__I-ORG and__O Prevention6__O the__O T-SPOT__O test__O has__O had__O a__O significant__O impact__O on__O the__O accuracy__O of__O TB__B-ORG diagnosis__O worldwide__O since__O its__O commercial__O release__O in__O 2004.__O
Accurate__O Diagnosis:__O The__O ability__O to__O diagnose__O TB__O more__O rapidly,__O specifically__O and__O sensitively__O than__O the__O alternative__O TST__B-ORG method__O is__O a__O major__O impact__O of__O the__O T-SPOT__B-ORG test1__O 7__O 8.__O
The__O TST__O method__O of__O diagnosis__O involves__O injecting__O an__O extract__O of__O TB__B-ORG into__O a__O patients__O skin,__O waiting__O two__O to__O three__O days2,__O then__O examining__O the__O skin__O for__O lesions__O &#8212;__O with__O an__O inflamed__O lesion__O indicating__O exposure__O to__O TB.__B-LOC
Diagnosing__O TB__O with__O the__O T-SPOT__O test__O is__O faster,__O easier__O to__O administer,__O and__O easier__O to__O read__O than__O the__O TST__B-ORG method7.__O
By__O taking__O a__O small__O blood__O sample__O from__O the__O patient,__O the__O T-SPOT__O test__O can__O give__O a__O result__O in__O under__O 24__O hours1.__O
The__O T-SPOT__O test__O is__O also__O easy__O to__O read__O and,__O because__O it__O measures__O cell__O numbers,__O it__O is__O highly__O quantitative.__O
In__O contrast,__O the__O TST__O test__O is__O frequently__O difficult__O to__O interpret,__O particularly__O in__O patients__O where__O the__O swelling__O is__O difficult__O to__O read,__O such__O as__O children__O with__O sensitive__O skin9__O or__O patients__O with__O conditions__O like__O rheumatic__O disease__O (which__O can__O cause__O skin__O swelling)10.__O
Interpretation__O of__O the__O TST__O test__O is__O a__O significant__O issue,__O particularly__O for__O doctors__O in__O developed__O countries,__O who__O are__O less__O experienced__O in__O examining__O the__O skin__O lesions__O produced__O by__O the__O TST__B-ORG method.__O
By__O using__O proteins__O that__O are__O specific__O to__O TB__B-ORG infection,__O rather__O than__O BCG,__O the__O T-SPOT__B-ORG test__O is__O more__O effective__O than__O the__O TST__B-ORG method__O in__O distinguishing__O between__O patients__O infected__O with__O TB__O and__O those__O who__O have__O simply__O been__O vaccinated__O 1,11.__O
The__O T-SPOT__O test__O is__O also__O far__O more__O accurate__O than__O the__O TST__B-ORG method__O in__O identifying__O individuals__O who__O have__O latent__O TB__B-ORG infection5,12__O .__O
Policy__O and__O Guidelines:__O The__O commercial__O availability__O and__O superior__O diagnostic__O value__O of__O the__O T-SPOT__B-MISC test__O has__O had__O an__O impact__O on__O global__O health__O policy__O and__O guidelines.__O
Since__O its__O commercial__O approval__O in__O 2004__O the__O T-SPOT__B-ORG test__O has__O been__O included__O in__O TB__O control__O guidelines__O in__O the__O USA__B-LOC (Centers__O for__O Disease__B-ORG Control__I-ORG and__I-ORG Prevention)__I-ORG and__I-ORG Europe,__I-ORG with__O more__O than__O 20__O countries__O now__O recommending__O the__O T-SPOT__B-ORG test__O to__O diagnose__O and__O screen__O patients__O for__O TB__B-ORG infection6__O 13.__O
In__O 2011__O the__O UK__B-ORG National__I-ORG Institute__I-ORG for__I-ORG Health__I-ORG and__I-ORG Clinical__I-ORG Excellence__I-ORG (NICE)__I-ORG updated__O their__O guidelines__O on__O control__O and__O prevention,__O recommending__O interferon-__O gamma__O release__O assays,__O such__O as__O the__O T-SPOT__B-ORG test,__O for__O use__O in__O a__O number__O of__O diagnostic__O situations14,__O including:__O In__O a__O TB__B-ORG outbreak,__O when__O large__O numbers__O of__O individuals__O need__O to__O be__O screened;__O For__O migrants__O between__O 16__O and__O 34__O years__O of__O age,__O coming__O from__O high__O incidence__O countries;__O Patients__O who__O suffer__O from__O immunodeficiency;__O NHS__B-ORG employees__O who__O have__O had__O contact__O with__O patients__O in__O a__O high__O incidence__O setting;__O and__O For__O individuals__O who__O have__O been__O vaccinated__O against__O TB,__B-ORG and__O those__O who__O have__O tested__O positive__O in__O a__O TST__O test.__O
Commercialisation__O and__O Reach:__B-PER Manufactured__I-PER by__O Oxford__B-ORG Immunotec__I-ORG Ltd,__I-ORG the__O T-SPOT.TB__B-ORG test__O was__O commercially__O approved__O for__O sale__O in__O Europe__B-LOC in__O 2004.__O
T-SPOT.TB__O sales__O have__O substantially__O increased__O since__O their__O first__O year__O on__O the__O market,__O growing__O from__O 2,000__O tests__O sold__O in__O 2004__O to__O 500,000__O in__O 2011.__O
While__O the__O cost__O of__O the__O T-SPOT.__O
TB__O test__O is__O &#163;30,__O in__O comparison__O to__O the__O TST__O (which__O is__O sold__O for__O around__O &#163;2),__O the__O accuracy__O of__O the__O T-SPOT.TB__B-MISC test__O effectively__O eliminates__O wasted__O resources__O in__O following__O up__O patients__O with__O false__O positive__O TST__B-ORG results,__O avoiding__O greater__O costs__O related__O to__O the__O treatment__O of__O TB__B-ORG in__O those__O who__O receive__O false__O negative__O TST__B-ORG results15.__O
Tests__O have__O been__O sold__O predominately__O to__O developed__O countries__O such__O as__O the__O USA,__B-ORG Germany,__I-ORG UK,__I-ORG Switzerland__I-ORG and__O France,__B-LOC and__O have__O been__O requested__O by__O clinicians__O from__O a__O variety__O of__O specialties__O including:__O pulmonology,__O occupational__O health,__O public__O health__O and__O infectious__O disease15.__O
